HRP20180130T1 - Protutumorsko sredstvo i postupak predviđanja terapijskog učinka za pacijente s kolorektalnim rakom s mutacijom kras - Google Patents
Protutumorsko sredstvo i postupak predviđanja terapijskog učinka za pacijente s kolorektalnim rakom s mutacijom kras Download PDFInfo
- Publication number
- HRP20180130T1 HRP20180130T1 HRP20180130TT HRP20180130T HRP20180130T1 HR P20180130 T1 HRP20180130 T1 HR P20180130T1 HR P20180130T T HRP20180130T T HR P20180130TT HR P20180130 T HRP20180130 T HR P20180130T HR P20180130 T1 HRP20180130 T1 HR P20180130T1
- Authority
- HR
- Croatia
- Prior art keywords
- colorectal cancer
- antitumor agent
- patient
- mutation
- kras
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011177838 | 2011-08-16 | ||
| EP12824342.5A EP2746404B1 (en) | 2011-08-16 | 2012-08-15 | Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer |
| PCT/JP2012/070745 WO2013024865A1 (ja) | 2011-08-16 | 2012-08-15 | Ｋｒａｓ遺伝子変異型の結腸直腸癌患者に対する抗腫瘍剤及び治療効果予測方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180130T1 true HRP20180130T1 (hr) | 2018-04-06 |
Family
ID=47715182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180130TT HRP20180130T1 (hr) | 2011-08-16 | 2012-08-15 | Protutumorsko sredstvo i postupak predviđanja terapijskog učinka za pacijente s kolorektalnim rakom s mutacijom kras |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9371380B2 (enExample) |
| EP (1) | EP2746404B1 (enExample) |
| JP (1) | JP5832541B2 (enExample) |
| KR (1) | KR101693090B1 (enExample) |
| CN (1) | CN103764847B (enExample) |
| AU (1) | AU2012295841B2 (enExample) |
| CY (1) | CY1119869T1 (enExample) |
| DK (1) | DK2746404T3 (enExample) |
| ES (1) | ES2659264T3 (enExample) |
| HR (1) | HRP20180130T1 (enExample) |
| HU (1) | HUE035347T2 (enExample) |
| LT (1) | LT2746404T (enExample) |
| NO (1) | NO2746404T3 (enExample) |
| PL (1) | PL2746404T3 (enExample) |
| PT (1) | PT2746404T (enExample) |
| RS (1) | RS56911B1 (enExample) |
| RU (1) | RU2585528C2 (enExample) |
| SI (1) | SI2746404T1 (enExample) |
| SM (1) | SMT201800108T1 (enExample) |
| TW (1) | TWI550089B (enExample) |
| WO (1) | WO2013024865A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2998742A4 (en) * | 2013-05-17 | 2017-01-18 | Taiho Pharmaceutical Co., Ltd. | Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased |
| EP3328394A4 (en) | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | CONCATEMEE peptide epitope RNAs |
| UA123403C2 (uk) * | 2016-02-05 | 2021-03-31 | Тайхо Фармасьютікал Ко., Лтд. | Спосіб лікування хворих на рак з тяжкою нирковою недостатністю |
| AU2017397458B2 (en) * | 2017-02-01 | 2025-07-10 | Modernatx, Inc. | RNA cancer vaccines |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1849470T5 (pl) | 2005-01-26 | 2024-06-10 | Taiho Pharmaceutical Co., Ltd. | Lek przeciwrakowy zawierający alfa,alfa,alfa-trifluorotymidynę i inhibitor fosforylazy tymidynowej |
| US7799783B2 (en) | 2005-01-26 | 2010-09-21 | Taiho Pharmaceutical Co., Ltd. | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
-
2012
- 2012-08-15 KR KR1020147006642A patent/KR101693090B1/ko active Active
- 2012-08-15 PL PL12824342T patent/PL2746404T3/pl unknown
- 2012-08-15 EP EP12824342.5A patent/EP2746404B1/en active Active
- 2012-08-15 CN CN201280040055.4A patent/CN103764847B/zh active Active
- 2012-08-15 JP JP2013529023A patent/JP5832541B2/ja active Active
- 2012-08-15 DK DK12824342.5T patent/DK2746404T3/en active
- 2012-08-15 SM SM20180108T patent/SMT201800108T1/it unknown
- 2012-08-15 US US14/238,569 patent/US9371380B2/en active Active
- 2012-08-15 LT LTEP12824342.5T patent/LT2746404T/lt unknown
- 2012-08-15 AU AU2012295841A patent/AU2012295841B2/en active Active
- 2012-08-15 WO PCT/JP2012/070745 patent/WO2013024865A1/ja not_active Ceased
- 2012-08-15 NO NO12824342A patent/NO2746404T3/no unknown
- 2012-08-15 SI SI201231194T patent/SI2746404T1/en unknown
- 2012-08-15 HR HRP20180130TT patent/HRP20180130T1/hr unknown
- 2012-08-15 ES ES12824342.5T patent/ES2659264T3/es active Active
- 2012-08-15 RU RU2014109999/10A patent/RU2585528C2/ru active
- 2012-08-15 HU HUE12824342A patent/HUE035347T2/en unknown
- 2012-08-15 RS RS20180124A patent/RS56911B1/sr unknown
- 2012-08-15 PT PT128243425T patent/PT2746404T/pt unknown
- 2012-08-16 TW TW101129724A patent/TWI550089B/zh active
-
2018
- 2018-01-31 CY CY20181100119T patent/CY1119869T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2013024865A1 (ja) | 2015-03-05 |
| JP5832541B2 (ja) | 2015-12-16 |
| ES2659264T3 (es) | 2018-03-14 |
| NO2746404T3 (enExample) | 2018-05-05 |
| TW201319257A (zh) | 2013-05-16 |
| WO2013024865A1 (ja) | 2013-02-21 |
| RU2585528C2 (ru) | 2016-05-27 |
| TWI550089B (zh) | 2016-09-21 |
| EP2746404B1 (en) | 2017-12-06 |
| EP2746404A1 (en) | 2014-06-25 |
| SMT201800108T1 (it) | 2018-05-02 |
| RU2014109999A (ru) | 2015-10-10 |
| SI2746404T1 (en) | 2018-04-30 |
| DK2746404T3 (en) | 2018-01-15 |
| CY1119869T1 (el) | 2018-06-27 |
| HK1197086A1 (zh) | 2015-01-02 |
| CN103764847B (zh) | 2016-05-11 |
| HUE035347T2 (en) | 2018-05-02 |
| PT2746404T (pt) | 2018-01-10 |
| PL2746404T3 (pl) | 2018-04-30 |
| CN103764847A (zh) | 2014-04-30 |
| KR20140057328A (ko) | 2014-05-12 |
| AU2012295841B2 (en) | 2015-12-10 |
| RS56911B1 (sr) | 2018-05-31 |
| EP2746404A4 (en) | 2015-04-08 |
| US9371380B2 (en) | 2016-06-21 |
| AU2012295841A1 (en) | 2014-04-03 |
| LT2746404T (lt) | 2018-04-25 |
| US20140213602A1 (en) | 2014-07-31 |
| KR101693090B1 (ko) | 2017-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017014381A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| MX358517B (es) | Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon. | |
| MX363584B (es) | Expresión génica basada en arnm para personalizar la terapia del cáncer al paciente con un antagonista de mdm2. | |
| UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
| NZ627443A (en) | Biological markers for identifying patients for treatment with vegf antagonists | |
| EA201391114A1 (ru) | Способы использования alk-ингибиторов | |
| MX376652B (es) | Método para determinar la eficacia de una terapia con fármacos de direccionamiento a glipicano 3 (gpc3) contra cáncer. | |
| EA201491584A1 (ru) | Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor | |
| JO3283B1 (ar) | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) | |
| PH12014501930A1 (en) | Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status | |
| HK1209758A1 (en) | Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies | |
| EA201401353A1 (ru) | Биомаркеры для определения эффективной ответной реакции на лечение пациентов с гепатоцеллюлярной карциномой (гцк) | |
| UA117556C2 (uk) | Спосіб збільшення ефективності терапевтичного засобу шляхом введення метотрексату | |
| HK1208057A1 (en) | Breast cancer prognosis, prediction of progesterone receptor subtype and prediction of response to antiprogestin treatment based on gene expression | |
| HRP20180130T1 (hr) | Protutumorsko sredstvo i postupak predviđanja terapijskog učinka za pacijente s kolorektalnim rakom s mutacijom kras | |
| PL2729008T3 (pl) | Systemy, sposoby i formulacje do leczenia raka | |
| EA201691385A1 (ru) | Комбинированная терапия рака | |
| MX2016004212A (es) | Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas. | |
| BR112017005336A2 (pt) | método de tratamento de cânceres sólidos e/ou metástases dos mesmos, medicamentos com essa finalidade e método para prever o resultado clínico de tratamento de cânceres sólidos e/ou metástases dos mesmos | |
| WO2013130465A3 (en) | Gene expression markers for prediction of efficacy of platinum-based chemotherapy drugs | |
| BR112013019080A2 (pt) | métodos para o tratamento do câncer, do nsclc e do câncer colorretal em um paciente humano e artigo de manufatura | |
| EA201501095A1 (ru) | Эффективное лечение нмрл и прогностический клинический маркер чувствительной к лечению опухоли | |
| BR112014019034A8 (pt) | Método para tratamento de câncer | |
| WO2012040656A3 (en) | Biomarkers to track response to scv-07 | |
| UA82125U (ru) | Способ прогнозирования рефрактур у больных с ложными суставами |